董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey R. Ajer | 男 | Director | 62 | 47.24万美元 | 未持股 | 2025-12-31 |
| Diana Brainard | 女 | Director | 54 | 未披露 | 未持股 | 2025-12-31 |
| Roy A. Whitfield | 男 | Director | 71 | 50.24万美元 | 未持股 | 2025-12-31 |
| Robert B. Chess | 男 | Chairman of the Board, Director | 68 | 50.34万美元 | 未持股 | 2025-12-31 |
| Howard W. Robin | 男 | Director, President and Chief Executive Officer | 72 | 1124.15万美元 | 未持股 | 2025-12-31 |
| R. Scott Greer | 男 | Director | 66 | 49.49万美元 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sandra Gardiner | 女 | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | 60 | 未披露 | 未持股 | 2025-12-31 |
| Jonathan Zalevsky | 男 | Senior Vice President and Chief Research and Development Officer | 50 | 494.15万美元 | 未持股 | 2025-12-31 |
| Elizabeth Zhang | 女 | Vice President, Legal and Corporate Counsel | -- | 未披露 | 未持股 | 2025-12-31 |
| Howard W. Robin | 男 | Director, President and Chief Executive Officer | 72 | 1124.15万美元 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Jeffrey R. Ajer
-
Jeffrey R. Ajer于2017年9月被任命为我们的董事会成员。Ajer先生目前担任Biomarin Pharmaceutical Inc.“；BioMarin”；的执行副总裁兼首席商务官，这是一家全球性的生物技术公司，为患有严重和危及生命的罕见疾病的人开发和商业化创新疗法。从2012年10月到2014年1月，Ajer先生担任BioMarin的高级副总裁兼首席商务官。从2009年4月到2012年10月，他曾担任BioMarin公司的美洲商业运营副总裁，在那里他曾负责整个美洲的商业运营，并领导BioMarin公司的产品营销、报销和销售运营。在加入BioMarin之前，Ajer先生从2003年11月开始在健赞公司（“；Genzyme”；）担任多个职位，最近的职位是从2004年12月到2005年8月担任全球移植运营副总裁。
Jeffrey R. Ajer, was appointed to our board of directors in September 2017. Mr. Ajer currently serves as Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical Inc. "BioMarin", a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. From October 2012 to January 2014 Mr. Ajer served as Senior Vice President and Chief Commercial Officer of BioMarin. From April 2009 to October 2012 Mr. Ajer served as BioMarin's Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation ("Genzyme") beginning in November 2003 most recently as Vice President, Global Transplant Operations from December 2004 to August 2005. - Jeffrey R. Ajer于2017年9月被任命为我们的董事会成员。Ajer先生目前担任Biomarin Pharmaceutical Inc.“；BioMarin”；的执行副总裁兼首席商务官，这是一家全球性的生物技术公司，为患有严重和危及生命的罕见疾病的人开发和商业化创新疗法。从2012年10月到2014年1月，Ajer先生担任BioMarin的高级副总裁兼首席商务官。从2009年4月到2012年10月，他曾担任BioMarin公司的美洲商业运营副总裁，在那里他曾负责整个美洲的商业运营，并领导BioMarin公司的产品营销、报销和销售运营。在加入BioMarin之前，Ajer先生从2003年11月开始在健赞公司（“；Genzyme”；）担任多个职位，最近的职位是从2004年12月到2005年8月担任全球移植运营副总裁。
- Jeffrey R. Ajer, was appointed to our board of directors in September 2017. Mr. Ajer currently serves as Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical Inc. "BioMarin", a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. From October 2012 to January 2014 Mr. Ajer served as Senior Vice President and Chief Commercial Officer of BioMarin. From April 2009 to October 2012 Mr. Ajer served as BioMarin's Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation ("Genzyme") beginning in November 2003 most recently as Vice President, Global Transplant Operations from December 2004 to August 2005.
- Diana Brainard
-
Diana Brainard自2020年7月以来一直担任我们的董事会成员。Brainard博士自2018年以来一直担任吉利德科学公司高级副总裁和病毒学治疗领域负责人，此前她曾于2015年至2018年担任肝脏疾病Vice President。Brainard博士在布朗大学（Brown University）获得学士学位，在杜兰大学医学院（Tulane University School of Medicine）获得医学博士学位。
Diana Brainard has served as member of Board of Directors since July 2020. Dr. Brainard has served as Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, Inc. since 2018 where she was previously Vice President of Liver Diseases from 2015 to 2018. Dr. Brainard obtained her BS degree from Brown University and her M.D. from Tulane University School of Medicine. - Diana Brainard自2020年7月以来一直担任我们的董事会成员。Brainard博士自2018年以来一直担任吉利德科学公司高级副总裁和病毒学治疗领域负责人，此前她曾于2015年至2018年担任肝脏疾病Vice President。Brainard博士在布朗大学（Brown University）获得学士学位，在杜兰大学医学院（Tulane University School of Medicine）获得医学博士学位。
- Diana Brainard has served as member of Board of Directors since July 2020. Dr. Brainard has served as Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, Inc. since 2018 where she was previously Vice President of Liver Diseases from 2015 to 2018. Dr. Brainard obtained her BS degree from Brown University and her M.D. from Tulane University School of Medicine.
- Roy A. Whitfield
-
Roy A. Whitfield，2000年8月起，担任本公司董事。他曾担任Incyte Corporation的董事长、首席执行官，这是他在1991年参与创办的药物研发公司。1993年1月至2001年11月，他担任Incyte Corporation的首席执行官；2001年11月对2003年6月，担任其董事长；1991年至2014年1月，担任董事。1984-1989，他在医疗器械公司Technicon Instruments Corporation及其前身Cooper Biomedical担任过运营和业务的高级职务，Cooper Biomedical是一个生物技术与医疗诊断公司。加入Technicon之前，他在Boston Consulting Group的国际咨询业务部工作了7年。他目前是Illumina、Station X的董事，前者是分析基因变异和生物功能的综合系统的开发、生产、销售商，后者是一个私营公司。他还从2008年2月起，担任Bioseek的执行董事长。他在Oxford University获得数学学士学位，在Stanford University获得工商管理硕士学位。
Roy A. Whitfield,has served as director since August 2000 and as Lead Independent Director since January 2019. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation ("Incyte"), a drug discovery and development company he co-founded in 1991. From January 1993 to November 2001, Mr. Whitfield served as its Chief Executive Officer and from November 2001 until June 2003 as its Chairman. He also served as a director of Incyte from 1991 to January 2014. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation ("Technicon"), a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Prior to his work at Technicon, Mr. Whitfield spent seven years with the Boston Consulting Group's international consulting practice. Mr. Whitfield received a B.S. in mathematics from Oxford University and an M.B.A. from Stanford University. - Roy A. Whitfield，2000年8月起，担任本公司董事。他曾担任Incyte Corporation的董事长、首席执行官，这是他在1991年参与创办的药物研发公司。1993年1月至2001年11月，他担任Incyte Corporation的首席执行官；2001年11月对2003年6月，担任其董事长；1991年至2014年1月，担任董事。1984-1989，他在医疗器械公司Technicon Instruments Corporation及其前身Cooper Biomedical担任过运营和业务的高级职务，Cooper Biomedical是一个生物技术与医疗诊断公司。加入Technicon之前，他在Boston Consulting Group的国际咨询业务部工作了7年。他目前是Illumina、Station X的董事，前者是分析基因变异和生物功能的综合系统的开发、生产、销售商，后者是一个私营公司。他还从2008年2月起，担任Bioseek的执行董事长。他在Oxford University获得数学学士学位，在Stanford University获得工商管理硕士学位。
- Roy A. Whitfield,has served as director since August 2000 and as Lead Independent Director since January 2019. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation ("Incyte"), a drug discovery and development company he co-founded in 1991. From January 1993 to November 2001, Mr. Whitfield served as its Chief Executive Officer and from November 2001 until June 2003 as its Chairman. He also served as a director of Incyte from 1991 to January 2014. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation ("Technicon"), a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Prior to his work at Technicon, Mr. Whitfield spent seven years with the Boston Consulting Group's international consulting practice. Mr. Whitfield received a B.S. in mathematics from Oxford University and an M.B.A. from Stanford University.
- Robert B. Chess
-
Robert B. Chess，自2014年7月起担任Twist Bioscience Corporation董事会成员，并于2018年10月30日被任命为首席独立董事；Nektar Therapeutics的董事长，自1992年5月起担任董事。2006年3月至2007年1月，他担任本公司的代理总裁、首席执行官；1999年4月至2007年1月，担任执行董事长。1998年8月至2000年4月，他还担任本公司的联席首席执行官；1991年12月至1998年8月，担任总裁；1992年5月至1998年8月，担任首席执行官。之前，他曾是Penederm的联合创始人、总裁，这是一个上市的皮肤科制药公司，后来出售给Mylan Laboratories。他曾在Intel Corporation 和 Metaphor Computer Systems（现为IBM的分部）担任过管理职务；作为白宫实习生，他是布什总统白宫工作人员的第一批成员，曾担任White House Office of Economic and Domestic Policy的副主任。1997年直到2009年退休，他都是Biotechnology Industry Organization （BIO）的董事；也曾担任BIO新兴公司部门的主席，及其知识产权委员会联合主席。他是 Bio Ventures for Global Health的首任主席，目前依旧担任董事。他还是 California Institute of Technology的董事、技术转移委员会主席、经济发展委员会受托人。目前，他是OPX Biotechnologies的董事长，这是可再生燃料和化学品领域的私营公司；也是医疗器械私营公司Pelvalon的董事。他现任Stanford Graduate School of Business的教员，在MBA的课程中讲授关于启动技术公司和医疗行业的知识。他以优异成绩获得了California Institute of Technology的工程学士学位，并在Harvard University获得工商管理硕士学位。
Robert B. Chess,is the Chairman of board of directors and has served as a director since May 1992. From March 2006 until January 2007, Mr. Chess served as Acting President and Chief Executive Officer, and from April 1999 to January 2007, served as Executive Chairman. He also served as Co-Chief Executive Officer from August 1998 to April 2000, as President from December 1991 to August 1998, and as Chief Executive Officer from May 1992 to August 1998. Mr. Chess was previously the co-founder and President of Penederm, Inc., a publicly-traded dermatological pharmaceutical company that was sold to Mylan Laboratories. He has held management positions at Intel Corporation and Metaphor Computer Systems (now part of IBM), and was a member of the first President Bush's White House staff as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy. Mr. Chess serves on the board of directors and is the lead director of Twist Biosciences, a publicly-traded company in the synthetic biology field. He is Chairman of two private companies: Bighat Biosciences, which does ML-guided biologics design, and Issio Solutions, which is in the labor productivity software field. From 1997 until his retirement in 2009, Mr. Chess served on the board of directors of the Biotechnology Industry Organization ("BIO"). Mr. Chess served as Chairman of BIO's Emerging Companies Section and Co-Chairman of BIO's Intellectual Property Committee. Mr. Chess was the initial Chairman of Bio Ventures for Global Health and served on its Board through 2022. He currently is a member of the faculty of the Stanford Graduate School of Business, where he teaches courses in the MBA program on the healthcare industry and the business opportunity created by aging demographics and increased longevity. Mr. Chess received his B.S. degree in Engineering with honors from the California Institute of Technology and an M.B.A. from Harvard University. - Robert B. Chess，自2014年7月起担任Twist Bioscience Corporation董事会成员，并于2018年10月30日被任命为首席独立董事；Nektar Therapeutics的董事长，自1992年5月起担任董事。2006年3月至2007年1月，他担任本公司的代理总裁、首席执行官；1999年4月至2007年1月，担任执行董事长。1998年8月至2000年4月，他还担任本公司的联席首席执行官；1991年12月至1998年8月，担任总裁；1992年5月至1998年8月，担任首席执行官。之前，他曾是Penederm的联合创始人、总裁，这是一个上市的皮肤科制药公司，后来出售给Mylan Laboratories。他曾在Intel Corporation 和 Metaphor Computer Systems（现为IBM的分部）担任过管理职务；作为白宫实习生，他是布什总统白宫工作人员的第一批成员，曾担任White House Office of Economic and Domestic Policy的副主任。1997年直到2009年退休，他都是Biotechnology Industry Organization （BIO）的董事；也曾担任BIO新兴公司部门的主席，及其知识产权委员会联合主席。他是 Bio Ventures for Global Health的首任主席，目前依旧担任董事。他还是 California Institute of Technology的董事、技术转移委员会主席、经济发展委员会受托人。目前，他是OPX Biotechnologies的董事长，这是可再生燃料和化学品领域的私营公司；也是医疗器械私营公司Pelvalon的董事。他现任Stanford Graduate School of Business的教员，在MBA的课程中讲授关于启动技术公司和医疗行业的知识。他以优异成绩获得了California Institute of Technology的工程学士学位，并在Harvard University获得工商管理硕士学位。
- Robert B. Chess,is the Chairman of board of directors and has served as a director since May 1992. From March 2006 until January 2007, Mr. Chess served as Acting President and Chief Executive Officer, and from April 1999 to January 2007, served as Executive Chairman. He also served as Co-Chief Executive Officer from August 1998 to April 2000, as President from December 1991 to August 1998, and as Chief Executive Officer from May 1992 to August 1998. Mr. Chess was previously the co-founder and President of Penederm, Inc., a publicly-traded dermatological pharmaceutical company that was sold to Mylan Laboratories. He has held management positions at Intel Corporation and Metaphor Computer Systems (now part of IBM), and was a member of the first President Bush's White House staff as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy. Mr. Chess serves on the board of directors and is the lead director of Twist Biosciences, a publicly-traded company in the synthetic biology field. He is Chairman of two private companies: Bighat Biosciences, which does ML-guided biologics design, and Issio Solutions, which is in the labor productivity software field. From 1997 until his retirement in 2009, Mr. Chess served on the board of directors of the Biotechnology Industry Organization ("BIO"). Mr. Chess served as Chairman of BIO's Emerging Companies Section and Co-Chairman of BIO's Intellectual Property Committee. Mr. Chess was the initial Chairman of Bio Ventures for Global Health and served on its Board through 2022. He currently is a member of the faculty of the Stanford Graduate School of Business, where he teaches courses in the MBA program on the healthcare industry and the business opportunity created by aging demographics and increased longevity. Mr. Chess received his B.S. degree in Engineering with honors from the California Institute of Technology and an M.B.A. from Harvard University.
- Howard W. Robin
-
Howard W. Robin，2007年1月起，担任本公司的总裁、首席执行官；2007年2月起，担任董事。2001年7月至2006年11月，他担任生物技术公司Sirna Therapeutics的首席执行官、总裁、董事；2001年1月至2001年6月，担任其首席运营官、副总裁、董事。1991-2001，他担任Berlex Laboratories的企业副总裁、总经理，这是一个制药产品公司，也是Schering, AG的子公司；1987-1991，他担任其财务与业务开发副总裁、首席财务官。1984-1987，他担任Berlex的业务规划与开发总监。加入Berlex之前，他曾是Arthur Andersen & Co.的高级合伙人。1974年，他获得了Fairleigh Dickinson University的会计与财务学士学位。
Howard W. Robin,has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since February 2007. Mr. Robin has more than 40 years of successful biopharmaceutical experience managing clinical development and commercial operations. Prior to joining Nektar, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna from 2001 to 2006, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck. Prior to joining Sirna, Mr. Robin was Senior Vice President and General Manager of the therapeutics division of Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG, where he was responsible for the development of drugs, such as Betaseron(R) (Interferon beta-1b), the first therapy for multiple sclerosis, and Fludara(R) (fludarabine phosphate), the first therapy for chronic lymphocytic leukemia. These drugs generated annual global sales in excess of $1.5 billion. Prior to joining Berlex, Mr. Robin was a senior associate with Arthur Andersen & Co. Mr. Robin received his B.S. in Accounting and Finance from Fairleigh Dickinson University, where he previously served as a member of its Board of Trustees. - Howard W. Robin，2007年1月起，担任本公司的总裁、首席执行官；2007年2月起，担任董事。2001年7月至2006年11月，他担任生物技术公司Sirna Therapeutics的首席执行官、总裁、董事；2001年1月至2001年6月，担任其首席运营官、副总裁、董事。1991-2001，他担任Berlex Laboratories的企业副总裁、总经理，这是一个制药产品公司，也是Schering, AG的子公司；1987-1991，他担任其财务与业务开发副总裁、首席财务官。1984-1987，他担任Berlex的业务规划与开发总监。加入Berlex之前，他曾是Arthur Andersen & Co.的高级合伙人。1974年，他获得了Fairleigh Dickinson University的会计与财务学士学位。
- Howard W. Robin,has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since February 2007. Mr. Robin has more than 40 years of successful biopharmaceutical experience managing clinical development and commercial operations. Prior to joining Nektar, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna from 2001 to 2006, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck. Prior to joining Sirna, Mr. Robin was Senior Vice President and General Manager of the therapeutics division of Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG, where he was responsible for the development of drugs, such as Betaseron(R) (Interferon beta-1b), the first therapy for multiple sclerosis, and Fludara(R) (fludarabine phosphate), the first therapy for chronic lymphocytic leukemia. These drugs generated annual global sales in excess of $1.5 billion. Prior to joining Berlex, Mr. Robin was a senior associate with Arthur Andersen & Co. Mr. Robin received his B.S. in Accounting and Finance from Fairleigh Dickinson University, where he previously served as a member of its Board of Trustees.
- R. Scott Greer
-
R. Scott Greer，2010年2月起担任本公司董事；现任风投公司Numenor Ventures, LLC的总经理。1996年，他参与创办了Abgenix，该公司专门从事人类治疗性抗体的研究、开发和生产；1996年6月至2002年5月，他担任其首席执行官。他从1996年起担任其董事，从2000年起担任董事长，直到2006年4月该公司被Amgen收购。成立Abgenix之前，他在生物技术公司Cell Genesys担任过多个高级管理职务，最初是首席财务官、企业发展副总裁，后来担任企业发展高级副总裁；他在生物技术开发公司Genetics Institute也担任过多个职务。他从2003年起，担任生物技术公司Sirna Therapeutics的董事，从2005年起担任其董事长，直到2006年12月该公司被Merck & Co.收购。2001-2005，他是Illumina的董事，这是用于分析遗传变异和生物功能的集成系统的提供商；2001-2004，担任生物技术公司CV Therapeutics的董事。他目前担任StemCells, Inc.（纳斯达克代码：STEM）的董事，这是专注于干细胞治疗的生物制药公司；也担任Ablexis LLC的董事长，这是一个开发阶段的私营生物技术公司。他获得了Whitman College的经济学学士学位、Harvard University的工商管理硕士学位，曾是一名注册会计师。
R. Scott Greer,has served as director since February 2010. Mr. Greer currently serves as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He previously also served as a director of Abgenix from 1996 and Chairman of the board of directors from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix's formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc., a biotechnology research and development company. He previously served on the board of directors of Inogen, Inc., a medical device company that develops and markets oxygen therapy products from 2015-2021, Sientra, Inc., a medical aesthetics company from 2014-2018, Versartis, Inc., an endocrine focused biopharmaceutical company from 2014-2018, Auspex Pharmaceuticals, a biopharmaceutical company developing drugs for patients with movement disorders and other rare diseases from 2014-2015, StemCells, Inc., a biopharmaceutical company focused on stem cell therapeutics from 2010-2016, Ablexis, an antibody technology company, as its Chairman of the board of directors from 2010-2016, Sirna Therapeutics, Inc., a biotechnology company, from 2003, and as its Chairman of the board of directors from 2005, through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006. Mr. Greer previously also served as a member of the board of directors of Illumina, Inc., a provider of integrated systems for the analysis of genetic variation and biological function from 2001-2005 and of the board of directors of CV Therapeutics, Inc., a biotechnology company from 2001-2004. Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. degree from Harvard University. He also was a certified public accountant. - R. Scott Greer，2010年2月起担任本公司董事；现任风投公司Numenor Ventures, LLC的总经理。1996年，他参与创办了Abgenix，该公司专门从事人类治疗性抗体的研究、开发和生产；1996年6月至2002年5月，他担任其首席执行官。他从1996年起担任其董事，从2000年起担任董事长，直到2006年4月该公司被Amgen收购。成立Abgenix之前，他在生物技术公司Cell Genesys担任过多个高级管理职务，最初是首席财务官、企业发展副总裁，后来担任企业发展高级副总裁；他在生物技术开发公司Genetics Institute也担任过多个职务。他从2003年起，担任生物技术公司Sirna Therapeutics的董事，从2005年起担任其董事长，直到2006年12月该公司被Merck & Co.收购。2001-2005，他是Illumina的董事，这是用于分析遗传变异和生物功能的集成系统的提供商；2001-2004，担任生物技术公司CV Therapeutics的董事。他目前担任StemCells, Inc.（纳斯达克代码：STEM）的董事，这是专注于干细胞治疗的生物制药公司；也担任Ablexis LLC的董事长，这是一个开发阶段的私营生物技术公司。他获得了Whitman College的经济学学士学位、Harvard University的工商管理硕士学位，曾是一名注册会计师。
- R. Scott Greer,has served as director since February 2010. Mr. Greer currently serves as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He previously also served as a director of Abgenix from 1996 and Chairman of the board of directors from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix's formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc., a biotechnology research and development company. He previously served on the board of directors of Inogen, Inc., a medical device company that develops and markets oxygen therapy products from 2015-2021, Sientra, Inc., a medical aesthetics company from 2014-2018, Versartis, Inc., an endocrine focused biopharmaceutical company from 2014-2018, Auspex Pharmaceuticals, a biopharmaceutical company developing drugs for patients with movement disorders and other rare diseases from 2014-2015, StemCells, Inc., a biopharmaceutical company focused on stem cell therapeutics from 2010-2016, Ablexis, an antibody technology company, as its Chairman of the board of directors from 2010-2016, Sirna Therapeutics, Inc., a biotechnology company, from 2003, and as its Chairman of the board of directors from 2005, through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006. Mr. Greer previously also served as a member of the board of directors of Illumina, Inc., a provider of integrated systems for the analysis of genetic variation and biological function from 2001-2005 and of the board of directors of CV Therapeutics, Inc., a biotechnology company from 2001-2004. Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. degree from Harvard University. He also was a certified public accountant.
高管简历
中英对照 | 中文 | 英文- Sandra Gardiner
Sandra Gardiner，2014年7月起，担任本公司的首席财务官。2013年9月至2014年6月，她是医疗器械公司Aptus Endosystems, Inc的首席财务官、公司秘书。2011年10月至2013年5月，她是医疗器械公司Ventus Medical, Inc.的首席财务官、公司秘书。2010年5月至2011年10月，她是医疗保健诊断公司Vermillion, Inc.的副总裁、首席财务官。2009年2月至2010年5月，她是制药开发公司Bend Research, Inc的首席财务官、董事。2001-2009，她担任Lipid Sciences, Inc的首席财务官、公司秘书，这是开发阶段的生物技术公司。她在University of California, Davis获得管理经济学士学位。
Sandra Gardiner has served as a member of Board since Augt 2024. Ms. Gardiner has been a partner at FLG Partners since March 2025. Ms. Gardiner previoly served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc. (Nasdaq: PLSE) beten November 2019 and November 2022, and a director of Lucira Health, Inc. (Nasdaq: LHDX) beten Augt 2020 and February 2023. From December 2017 to November 2019, Ms. Gardiner was the Executive Vice President and Chief Financial Officer of Cutera, Inc. (Nasdaq: CUTR). Prior to that, she held Chief Financial Officer roles in both domestic and global companies. Through FLG Partners, Ms. Gardiner serves in an executive capacity to vario companies. Ms. Gardiner holds a B.A. in Management Economics from the University of California, Davis.- Sandra Gardiner，2014年7月起，担任本公司的首席财务官。2013年9月至2014年6月，她是医疗器械公司Aptus Endosystems, Inc的首席财务官、公司秘书。2011年10月至2013年5月，她是医疗器械公司Ventus Medical, Inc.的首席财务官、公司秘书。2010年5月至2011年10月，她是医疗保健诊断公司Vermillion, Inc.的副总裁、首席财务官。2009年2月至2010年5月，她是制药开发公司Bend Research, Inc的首席财务官、董事。2001-2009，她担任Lipid Sciences, Inc的首席财务官、公司秘书，这是开发阶段的生物技术公司。她在University of California, Davis获得管理经济学士学位。
- Sandra Gardiner has served as a member of Board since Augt 2024. Ms. Gardiner has been a partner at FLG Partners since March 2025. Ms. Gardiner previoly served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc. (Nasdaq: PLSE) beten November 2019 and November 2022, and a director of Lucira Health, Inc. (Nasdaq: LHDX) beten Augt 2020 and February 2023. From December 2017 to November 2019, Ms. Gardiner was the Executive Vice President and Chief Financial Officer of Cutera, Inc. (Nasdaq: CUTR). Prior to that, she held Chief Financial Officer roles in both domestic and global companies. Through FLG Partners, Ms. Gardiner serves in an executive capacity to vario companies. Ms. Gardiner holds a B.A. in Management Economics from the University of California, Davis.
- Jonathan Zalevsky
Jonathan Zalevsky自2019年10月起担任我们的首席研发官。Zalevsky博士于2017年4月至2017年11月担任我们的高级副总裁，生物学和临床前开发，并于2017年11月至2019年10月担任我们的高级副总裁，研究和首席科学官。2015年7月至2017年4月，Zalevsky博士担任我们的Vice President，生物学和临床前开发。在加入Nektar之前，Zalevsky博士是Takeda Pharmaceuticals的全球Vice President和炎症药物开发部门的负责人。在武田工作之前，Zalevsky博士曾在Xencor，Inc.担任多个研究与开发职位Zalevsky博士在加州大学旧金山分校（University of California，San Francisco）的Tetrad项目获得生物化学博士学位。他在科罗拉多大学博尔德分校（University of Colorado at Boulder）获得生物化学和分子、细胞和发育生物学双学士学位。
Jonathan Zalevsky has served as a member of board of directors since November 2021. He has also served as a director of InveniAI since 2017, of AlphaMeld Corporation since December 2024, and of ReAlta Life Sciences from November 2019 to December 2023. He has served as the Chief Research and Development Officer of Nektar Therapeutics since October 2019 and previoly served as its Chief Scientific Officer from 2017 to 2019. Dr. Zalevsky holds a Ph.D. in biochemistry from the Tetrad Program at the University of California, San Francisco and dual B.S. degrees in biochemistry and molecular, cellular, and developmental biology from the University of Colorado at Boulder.- Jonathan Zalevsky自2019年10月起担任我们的首席研发官。Zalevsky博士于2017年4月至2017年11月担任我们的高级副总裁，生物学和临床前开发，并于2017年11月至2019年10月担任我们的高级副总裁，研究和首席科学官。2015年7月至2017年4月，Zalevsky博士担任我们的Vice President，生物学和临床前开发。在加入Nektar之前，Zalevsky博士是Takeda Pharmaceuticals的全球Vice President和炎症药物开发部门的负责人。在武田工作之前，Zalevsky博士曾在Xencor，Inc.担任多个研究与开发职位Zalevsky博士在加州大学旧金山分校（University of California，San Francisco）的Tetrad项目获得生物化学博士学位。他在科罗拉多大学博尔德分校（University of Colorado at Boulder）获得生物化学和分子、细胞和发育生物学双学士学位。
- Jonathan Zalevsky has served as a member of board of directors since November 2021. He has also served as a director of InveniAI since 2017, of AlphaMeld Corporation since December 2024, and of ReAlta Life Sciences from November 2019 to December 2023. He has served as the Chief Research and Development Officer of Nektar Therapeutics since October 2019 and previoly served as its Chief Scientific Officer from 2017 to 2019. Dr. Zalevsky holds a Ph.D. in biochemistry from the Tetrad Program at the University of California, San Francisco and dual B.S. degrees in biochemistry and molecular, cellular, and developmental biology from the University of Colorado at Boulder.
- Elizabeth Zhang
Elizabeth Zhang自2021年以来一直在Nektar工作，此前曾在纽约市的Cravath，Swaine & Moore LLP和旧金山的Gibson，Dunn & Crutcher LLP任职。张女士拥有哈佛学院神经生物学文学学士学位、牛津大学神经科学理学硕士学位和哈佛法学院法学博士学位。
Elizabeth Zhang,has been with Nektar since 2021 after prior positions at Cravath, Swaine & Moore LLP in New York City and Gibson, Dunn & Crutcher LLP in San Francisco. Ms. Zhang holds a Bachelor of Arts in Neurobiology from Harvard College, a Master of Science in Neuroscience from the University of Oxford, and a Juris Doctor from Harvard Law School.- Elizabeth Zhang自2021年以来一直在Nektar工作，此前曾在纽约市的Cravath，Swaine & Moore LLP和旧金山的Gibson，Dunn & Crutcher LLP任职。张女士拥有哈佛学院神经生物学文学学士学位、牛津大学神经科学理学硕士学位和哈佛法学院法学博士学位。
- Elizabeth Zhang,has been with Nektar since 2021 after prior positions at Cravath, Swaine & Moore LLP in New York City and Gibson, Dunn & Crutcher LLP in San Francisco. Ms. Zhang holds a Bachelor of Arts in Neurobiology from Harvard College, a Master of Science in Neuroscience from the University of Oxford, and a Juris Doctor from Harvard Law School.
- Howard W. Robin
Howard W. Robin，2007年1月起，担任本公司的总裁、首席执行官；2007年2月起，担任董事。2001年7月至2006年11月，他担任生物技术公司Sirna Therapeutics的首席执行官、总裁、董事；2001年1月至2001年6月，担任其首席运营官、副总裁、董事。1991-2001，他担任Berlex Laboratories的企业副总裁、总经理，这是一个制药产品公司，也是Schering, AG的子公司；1987-1991，他担任其财务与业务开发副总裁、首席财务官。1984-1987，他担任Berlex的业务规划与开发总监。加入Berlex之前，他曾是Arthur Andersen & Co.的高级合伙人。1974年，他获得了Fairleigh Dickinson University的会计与财务学士学位。
Howard W. Robin,has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since February 2007. Mr. Robin has more than 40 years of successful biopharmaceutical experience managing clinical development and commercial operations. Prior to joining Nektar, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna from 2001 to 2006, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck. Prior to joining Sirna, Mr. Robin was Senior Vice President and General Manager of the therapeutics division of Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG, where he was responsible for the development of drugs, such as Betaseron(R) (Interferon beta-1b), the first therapy for multiple sclerosis, and Fludara(R) (fludarabine phosphate), the first therapy for chronic lymphocytic leukemia. These drugs generated annual global sales in excess of $1.5 billion. Prior to joining Berlex, Mr. Robin was a senior associate with Arthur Andersen & Co. Mr. Robin received his B.S. in Accounting and Finance from Fairleigh Dickinson University, where he previously served as a member of its Board of Trustees.- Howard W. Robin，2007年1月起，担任本公司的总裁、首席执行官；2007年2月起，担任董事。2001年7月至2006年11月，他担任生物技术公司Sirna Therapeutics的首席执行官、总裁、董事；2001年1月至2001年6月，担任其首席运营官、副总裁、董事。1991-2001，他担任Berlex Laboratories的企业副总裁、总经理，这是一个制药产品公司，也是Schering, AG的子公司；1987-1991，他担任其财务与业务开发副总裁、首席财务官。1984-1987，他担任Berlex的业务规划与开发总监。加入Berlex之前，他曾是Arthur Andersen & Co.的高级合伙人。1974年，他获得了Fairleigh Dickinson University的会计与财务学士学位。
- Howard W. Robin,has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since February 2007. Mr. Robin has more than 40 years of successful biopharmaceutical experience managing clinical development and commercial operations. Prior to joining Nektar, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna from 2001 to 2006, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck. Prior to joining Sirna, Mr. Robin was Senior Vice President and General Manager of the therapeutics division of Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG, where he was responsible for the development of drugs, such as Betaseron(R) (Interferon beta-1b), the first therapy for multiple sclerosis, and Fludara(R) (fludarabine phosphate), the first therapy for chronic lymphocytic leukemia. These drugs generated annual global sales in excess of $1.5 billion. Prior to joining Berlex, Mr. Robin was a senior associate with Arthur Andersen & Co. Mr. Robin received his B.S. in Accounting and Finance from Fairleigh Dickinson University, where he previously served as a member of its Board of Trustees.